Home
Clinical Studies Testimonials
FAQ
Cold-fx, Box - 18 Capsules - $12.59
CAD
Cold-fx, Bottle - 60 Capsules - $25.49
CAD
Seven
Clinical Studies totaling 641
participants have shown the product to
be safe and effective including a
successful US FDA randomized
double-blind placebo-controlled trial.
COLD-fX®
prevents recurrent cold and
flu infections by 56% and significantly
reduces days of illness and symptom
severity.
A Health Canada authorized randomized,
double-blind, placebo-controlled trial
was conducted on 279 healthy adults from
the general population (18-65 years of
age) with a history of at least two
upper respiratory infections (colds) in
the previous year. COLD-fX (2 X 200
mg/day) taken for four months was shown
to significantly reduce (26%) the
average number and frequency of upper
respiratory infections per person versus
the placebo group. The incidence of
recurrent infections was reduced by 56%.
A reduction in the total number of days
suffered with cold or flu symptoms from
10.9 to 6.0, and a 31% reduction in the
severity of symptoms, was also observed
with COLD-fX treatment.
COLD-fX was
shown to significantly stimulate the
total number of T-lymphocytes and
T-helper lymphocytes, as well as Natural
Killer (NK) cells. The safety analysis
indicated that COLD-fX was safe and
well-tolerated.
COLD-fX® reduces risk of colds, flu and
respiratory illness by 89%.
A US FDA authorized randomized
double-blind, placebo-controlled trial
of COLD-fX® (CVT-E002), in
institutionalized older adults,
demonstrated COLD-fX® significantly
reduced the risk, by 89%, of developing
laboratory confirmed influenza or
respiratory syncytial virus (RSV) in a
senior population after 8-12 weeks of
treatment. At a dose of 400 mg daily (2
X 200 mg), COLD-fX® was shown to be
safe, well tolerated, and effective for
preventing acute respiratory illness due
to influenza and RSV. This trial also
demonstrated COLD-fX is safe and
complimentary to the flu vaccine.
A double-blind, placebo controlled study
of COLD-fX® in an immunocompetent
community dwelling of adults aged 65
years or older demonstrated a
statistically significant reduction in
the number of illnesses, the majority of
which were associated with respiratory
symptoms. The significant results
included a greater incidence of
respiratory symptoms in the placebo
group, 76%, versus 45% in COLD-fX® group
after 4 months of treatment at 400mg (2
X 200mg) daily. COLD-fX® was shown to be
safe and well tolerated.
COLD-fX® provides rapid recovery from
cold/flu symptoms and improves general
feeling of well-being.
An open study on 22 high performance
athletes demonstrated that 71% reported
COLD-fX® prevented the cold from
developing and improved how the
participants felt with chronic treatment
with COLD-fX®. Participants took 400 mg
(2 X 200 mg) daily for 8 months. 50%
reported that COLD-fX® allowed them to
recover faster from a cold after three
days of acute treatment at the onset of
cold and flu like symptoms. In the case
of acute treatment the athletes took 600
mg (3 X 200 mg) TID on day 1 totaling 9
capsules, then took 400 mg (2 X 200 mg)
TID on day 2 totaling 6 capsules, and
200 mg (1 X 200 mg) TID on day 3
totaling 3 capsules. In both cases COLD-fX®
was shown to be safe and well tolerated.
COLD-fX® positively regulates antiviral
cell-mediated immunity.
The specific influenza immune response
was evaluated using COLD-fX® versus
placebo in 37 high performance athletes.
COLD-fX®-treated participants taking 400
mg daily (2 X 200 mg) had altered immune
responses suggesting COLD-fX® treatment
may prevent the onset or reduce the
severity of symptoms related to colds
and flu and could do so by maintaining
the production of inflammatory and
immunologic mediators at consistent
levels. The levels of TNF-a and IL–2
trended down in the control group –50%,
and –25% respectively and remained the
same or increased in the COLD-fX®
treatment group which by 40% and 5%
respectively. This study showed that
COLD-fX® was safe and well tolerated.
COLD-fX® is safe for doping control
urinalysis.
A doping control urinalysis of COLD-fX®
was conducted under strict ethical and
International Olympic Committee (IOC)
doping control guidelines in 56 Canadian
athletes taking 400 mg daily (2 X 200
mg) for 28 days. The results
demonstrated that COLD-fX® does not
contain IOC-banned substances and that
COLD-fX® does not generate substances
within the body that might create a
positive doping control test. Athletes
and individuals in general can rely on
COLD-fX® as a cold-and-flu product that
will not interfere with test results by
the International Olympic Committee and
other governing organizations.
